Comparison between patients with and without ILD events
| With ILD events (n=17) | Without ILD events (n=146) | p Value | |
|---|---|---|---|
| Age—years | 66.4±9.5 | 60.3±12.1 | 0.071 |
| Gender—male/female—N | 6/11 | 41/105 | 0.575 |
| Stage of RA | |||
| Stage | 2.3±1.0 | 2.4±1.0 | 0.607 |
| Class | 2.1±0.4 | 2.1±0.6 | 0.589 |
| Patients with pre-existing ILD—N (%) | 14 (82) | 44 (30) | <0.001 |
| Biological therapy—N (%) | |||
| TNF inhibitors | 15 (88) | 87 (60) | 0.031 |
| Adalimumab | 1 (6) | 5 (3) | 0.489 |
| Etanercept | 9 (53) | 54 (37) | 0.292 |
| Infliximab | 5 (29) | 28 (19) | 0.342 |
| Non-TNF inhibitors | 2 (12) | 59 (40) | 0.031 |
| Anti-IL-6 receptor antibody | |||
| Tocilizumab | 2 (12) | 34 (23) | 0.367 |
| CTLA4-Ig | |||
| Abatacept | 0 (0) | 25 (17) | 0.077 |
Plus-minus values are means±SD.
CTLA4-Ig, cytotoxic T-lymphocyte antigen 4-immunoglobulin; ILD, interstitial lung disease; RA, rheumatoid arthritis; TNF, tumour necrosis factor.